PMA device
Melafind
Strata Skin Sciences, Inc. · Optical Diagnostic Device For Melanoma Detection (OYD, Class II) · First FDA decision Nov 1, 2011, newest Aug 18, 2016Skin cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
2
Naming "Melafind"
MAUDE reports
0
Brand "Melafind", since 2015
PubMed studies
24
Mentioning "Melafind"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Melafind
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- MELAFINDPMA supplement
P090012-S011 · Decided Aug 18, 2016 · 434 days after receipt · Normal 180 Day Track
Device type: Optical diagnostic device for melanoma detection (OYD) · General & Plastic Surgery
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Melafind", any status and sponsor, newest update first.
- Post-Approval Study of MelaFindTerminated
MELA Sciences, Inc.Not on our public-company list
NCT01700114 · 487 participants · Start Nov 2012 · Primary completion Jan 2016
Device: MelaFind · For: Melanoma
Sites: Englewood, Colorado; Tallahassee, Florida; Baltimore, Maryland · 6 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Melafind", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OYD
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1636-2015 · Started Apr 2, 2015 · Posted by FDA May 20, 2015
Reason given: The probability and histogram data within the Melafind's device displayed user interface lacks approval (not included in the PMA supplement).
Cause as FDA categorized it: Software design · Device type: Optical Diagnostic Device For Melanoma Detection (OYD)
Published research
The most relevant PubMed records for "Melafind"[tiab]. The summary above synthesizes these.
- Artificial Intelligence in Dermatology: A Comprehensive Review of Approved Applications, Clinical Implementation, and Future Directions.
Nahm WJ, Sohail N, Burshtein J, et al. · Int J Dermatol · 2025Review
- The diagnostic evaluation of MelaFind multi-spectral objective computer vision system.
Kupetsky EA, Ferris LK · Expert Opin Med Diagn · 2013
- Practical application of new technologies for melanoma diagnosis: Part I. Noninvasive approaches.
March J, Hand M, Grossman D · J Am Acad Dermatol · 2015Research Support, Non-U.S. Gov't, Review
- Diagnostic performance of the MelaFind device in a real-life clinical setting.
Fink C, Jaeger C, Jaeger K, et al. · J Dtsch Dermatol Ges · 2017Observational Study
- Diagnoseleistung des MelaFind-Geräts im klinischen Alltag.
Fink C, Jaeger C, Jaeger K, et al. · J Dtsch Dermatol Ges · 2017
- The performance of MelaFind: a prospective multicenter study.
Monheit G, Cognetta AB, Ferris L, et al. · Arch Dermatol · 2011Clinical Trial, Multicenter Study
- Advances in noninvasive imaging of melanoma.
Menge TD, Pellacani G · Semin Cutan Med Surg · 2016Review
- Histopathologic correlation of high-risk MelaFindTM lesions: a 3-year experience from a high-risk pigmented lesion clinic.
Shrivastava V, Bailin P, Elliott J, et al. · Int J Dermatol · 2019
- To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions.
Hauschild A, Chen SC, Weichenthal M, et al. · J Dtsch Dermatol Ges · 2014
- Computer-assisted diagnosis of melanoma.
Fuller C, Cellura AP, Hibler BP, et al. · Semin Cutan Med Surg · 2016Review
- The use of noninvasive imaging techniques in the diagnosis of melanoma: a prospective diagnostic accuracy study.
MacLellan AN, Price EL, Publicover-Brouwer P, et al. · J Am Acad Dermatol · 2021Comparative Study
- Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'?
Braun RP, Gutkowicz-Krusin D, Rabinovitz H, et al. · Dermatology · 2012Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.